Description:
S1007 Supplementary Follow-Up Form (FUS1007) Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=90C9DFFB-2463-84DB-E040-BB89AD437DC2
Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=90C9DFFB-2463-84DB-E040-BB89AD437DC2Keywords:
Versions (2)
- 8/27/12 8/27/12 -
- 1/9/15 1/9/15 - Martin Dugas
Uploaded on:
January 9, 2015
DOI:
To request one please log in.License :
Creative Commons BY-NC 3.0 LegacyModel comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Breast Cancer NCT01272037 Follow-Up - S1007 Supplementary Follow-Up Form (FUS1007) - 3139763v1.0
Instructions: Please submit at each follow up after completion of treatment until recurrence, at time of recurrence, and at protocol specified intervals after recurrence. All dates are MONTH, DAY, YEAR. Place an X in appropriate boxes. Circle AMENDED items in red and write AMENDED across the top of the form
- StudyEvent: S1007 Supplementary Follow-Up Form (FUS1007)